Effect of Posttransplant Diabetes Mellitus on Graft Loss After Living-Donor Kidney Transplant at a Single Institution

Maekawa, Yuka; Horie, Kengo; Iinuma, Koji; Takai, Manabu; Ohzawa, Kaori; Tsuchiya, Tomohiro; Kato, Daisuke; Taniguchi, Tomoki; Ito, Hiroki; Hishida, Seiji; Nakane, Keita; Mizutani, Kosuke; Koie, Takuya; Kato, Taku

doi:10.1016/j.transproceed.2019.10.025

Cited by 1 publication

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Japan, the incidence rate of PTDM was 15.1% at 5 years 31 . Additionally, Yuka et al’s study showed that graft loss was significantly higher in KT recipients with diabetes than in those without during the median 105.5-month follow-up period at a single institution 32 . In a Taiwanese population-based study, PTDM was related to MACEs and patient survival, especially in those who were comparatively young and had fewer comorbidities 20 .…”

Section: Discussionmentioning

confidence: 99%

Clinical outcomes of posttransplantation diabetes mellitus in kidney transplantation recipients: a nationwide population-based cohort study in Korea

Kang

Lee

Kang

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Posttransplantation diabetes mellitus (PTDM) is an important metabolic complication after KT that causes graft failure and cardiovascular complications in kidney transplantation (KT) recipients. Using the national claim data of South Korea, 7612 KT recipients between 2009 and 2017 were analyzed. PTDM was defined as a consecutive 30-day prescription history of antidiabetic medication after KT. Among these patients, 24.7% were diagnosed with PTDM, and 51.9% were diagnosed within 6 months after KT. Compared to patients without PTDM, those with PTDM were older, more likely to be men, more likely to be diagnosed with hypertension and cardio-cerebrovascular disease, and experienced more rejection episodes requiring high-dose steroid treatment after KT. During the follow-up, 607 DCGFs, 230 DWGFs, 244 MACEs, and 260 all-cause mortality events occurred. Patients with PTDM showed a higher risk of DCGF (adjusted hazard ratio [aHR] 1.49; 95% confidence interval [CI] 1.22–1.82; P < 0.001) and MACEs (aHR 1.76; 95% CI 1.33–2.31; P < 0.001) than patients without PTDM. The risks for all clinical outcomes were higher in the insulin group than in the non-use insulin group. PTDM in KT recipients resulted in both worse allograft and patient outcomes represented by DCGF and MACE, especially in patients needing insulin treatment.

show abstract

Section: Discussionmentioning

confidence: 99%